Anchyra Partners’s Takeda Pharmaceutical TAK Stock Holding History

Anchyra Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,466	Closed	-$231K	–	372
2026 Q1	$231K	Buy	+12,466	New	+$219K	0.07%	246

Other funds holding TAK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Managed Asset Portfolios Rochester, Michigan $875M AUM 41.9% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Anchyra Partners's TAK Position: Q2 2026 in Review

Anchyra Partners sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 12,466 shares — an estimated $231K sold.

Anchyra Partners first reported a position in TAK in Q1 2026 and held it in 1 quarter. The position peaked at $231K in Q1 2026. 201 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Anchyra Partners reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Anchyra Partners sold 12,466 Takeda Pharmaceutical shares in Q2 2026, an estimated $231K.
Anchyra Partners first reported a position in Takeda Pharmaceutical in Q1 2026 and held it in 1 quarter.
Anchyra Partners's Takeda Pharmaceutical position peaked at $231K in Q1 2026.
201 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.